Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse

Author:

Castro Andrea12ORCID,Goodman Aaron M.3,Rane Zachary4,Talwar James V.12,Frampton Garrett M.5,Morris Gerald P.6,Lippman Scott M.47,Zhang Xinlian8,Kurzrock Razelle9,Carter Hannah27ORCID

Affiliation:

1. 1 Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA, USA

2. 2 Division of Medical Genetics, Department of Medicine, University of California San Diego, La Jolla, CA, USA

3. 3 Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, La Jolla, CA, USA

4. 4 School of Medicine, University of California San Diego, La Jolla, CA, USA

5. 5 Foundation Medicine, Cambridge, MA, USA

6. 6 Department of Pathology, University of California San Diego, La Jolla, CA, USA

7. 7 Moores Cancer Center, University of California San Diego, La Jolla, CA, USA

8. 8 Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, CA, USA

9. 9 Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

Abstract

ABSTRACT Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure patients with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). However, many patients relapse or develop debilitating graft-versus-host disease. Transplant restores T-cell reactivity against tumor cells, implicating patient human leukocyte antigen (HLA)-dependent antigen presentation via the major histocompatibility complex as a determinant of response. We sought to identify characteristics of the HLA genotype that influence response in allo-HSCT patients. Methods We collected HLA genotype and panel-based somatic mutation profiles for 55 patients with AML and MDS and available data treated at the University of California San Diego Moores Cancer Center between May 2012 and January 2019. We evaluated characteristics of the HLA genotype relative to relapse-free time and overall survival (OS) post-allo-HSCT using univariable and multivariable regression. Results In multivariable regression, the presence of an autoimmune allele was significantly associated with relapse-free time (hazard ratio [HR], 0.25; p = 0.01) and OS (HR, 0.16; p < 0.005). The better potential of the donor HLA type to present peptides harboring driver mutations trended toward better relapse-free survival (HR, 0.45; p = 0.07) and significantly correlated with longer OS (HR, 0.33; p = 0.01) though only a minority of cases had an HLA mismatch. Conclusion In this single institution retrospective study of patients receiving allo-HSCT for relapsed AML/MDS, characteristics of an individual's HLA genotype (presence of an autoimmune allele and potential of the donor HLA to better present peptides representing driver mutations) were significantly associated with better outcomes. These findings suggest that HLA type may guide the optimal application of allo-HSCT and merit evaluation in larger cohorts. ClinicalTrials.gov Identifier: NCT02478931

Publisher

Innovative Healthcare Institute

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3